symp1

0

R. Jelliffe (U.S.A): State of the art

M. Tod (France): Population pharmacokinetics and drug evaluation.

I. Mac Dougall (U.K.): Rational design of novel erythtopoiesis stimulating protein: increased biological activity and relationship to patient population.

L. Balant (Switzerland): Population pharmacokinetics, interindividual variability and drug interactions.

P. Maire & N. Bleyzac (France): Control of pharmacokinetic variability: clinical applications in extreme aging.